Edarbi
(Azilsartan)ApprovedSmall molecule
TakedaAzilsartan is a medication that helps lower high blood pressure by relaxing blood vessels so blood flows more easily and the heart works more efficiently. It's used to treat high blood pressure, which can cause serious damage to organs like the heart, brain, and kidneys if left untreated.[2] Edarbi is currently approved and in use across 6 indications[4].[1]
Edarbi is one of 164 small molecule programs targeting Insulin resistance. It is currently in Approved.
6
Indications
18
Total Trials
0
Active Trials
163
Competitors
Pipeline
Status by Indication[4][1]
Indication
Competition
Competitive Landscape
1931 competitors in COVID-19
#DrugCompanyPhaseTrials
1Edarbi
TakedaApproved
Bnt162b2
BioNTechPreclinical
Nitrostat
VViatris Specialty LLC
Preclinical
HB-Admscs
HHope Biosciences Research Foundation
Preclinical
Sivelestat Sodium
TThe First Hospital of Jilin University
Preclinical
Netakimab
SSPH-BIOCAD (HK) Limited
Preclinical
Serology
UUniversity Hospital Center of Martinique
Preclinical
C21
VVicore Pharma AB
Preclinical
CAP-1002
CCapricor Inc.
Preclinical
Thrombolytic
FFaculty Hospital Kralovske Vinohrady
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Hypertension4 trials
Show 1 more trial
Essential Hypertension3 trials
Kidney Disease1 trial
Azilsartan in Patients With Diabetic Kidney Disease and Hypertension
Unknown status·SSecond Affiliated Hospital, School of Medicine, Zhejiang University·N/A·NCT05753696·106 enrolled
Blood Pressure1 trial
8 more indications
COVID-191 trial
Type 2 Diabetes Mellitus1 trial
Dyslipidemia1 trial
Insulin resistance1 trial
High Blood Pressure1 trial
Sources
References
- [1]
- [2]MedlinePlus Drug Information — Edarbi drug information. U.S. National Library of Medicine, National Institutes of Health.
- [3]
- [4]Open Targets Platform — Drug–disease associations for Azilsartan. EMBL-EBI & Wellcome Sanger Institute.
- [5]